Old prostate drug may spark brain cells in Parkinson's
NCT ID NCT07288450
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether terazosin, a drug currently used for an enlarged prostate, can boost energy production in brain cells of people with early Parkinson's disease. One hundred participants will receive either terazosin or a placebo for 6 months. Researchers will measure changes in energy molecules in the blood and brain to see if the drug hits its target.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Terazosin Hydrochloride
- What this could lead to
- If it works, this could point toward a treatment that slows Parkinson's by improving brain cell energy.
- What could go wrong
- This is a very early Phase 1/2 trial with only 100 people. It tests whether the drug hits its target in the body, not whether it improves symptoms. Many early trials do not lead to effective treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 50-80 years old at the time of enrollment with a diagnosis of idiopathic PD per the Movement Disorder Society's Diagnostic Criteria. * Subjects must NOT be taking more than 2 dopaminergic treatments for their PD at the time of enrollment. * Practically defined OFF Hoehn and Yahr score of 0-2. * Diagnosis of PD made within the preceding 3 years. Exclusion Criteria: * • Orthostatic hypotension at screening is defined as decrease in BP \> 20 mmHg systolic or \> 10 mmHg diastolic and HR increase \<20 bpm on transition from supine to sitting or standing. * Known allergy or previous adverse reaction to TZ or related compounds. * Current use of TZ or concurrent use of DZ, AZ, prazosin, or tamsulosin. * History of hepatic dysfunction. * History of clinically relevant anemia. * Secondary parkinsonism, drug-induced parkinsonism, Parkinson's-plus syndromes, or non-idiopathic PD. * PD including use of more than two dopaminergic medications at screening. * History of deep brain stimulation. * Dementia per Movement Disorder Society Level 1 criteria. * Traumatic brain injury or post-traumatic stress disorder. * Presence of a confounding acute or unstable medical, psychiatric, or orthopedic condition. * Unstable use of medications that modulate the central nervous system. * Uncontrolled major depression or bipolar affective disorder, or other mental health disorders that are, in the opinion of the site investigator, sufficiently severe to increase risk of experiencing an Adverse Drug Reaction (ADR). * Current suicidal ideation as measured by questions 4 or 5 of the Columbia-Suicide Severity Rating Scale. * Participants with insufficient decisional capacity to provide written informed consent determined by the site investigator. * Unstable use of antihypertensive medications.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Parkinson's disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Walking memory tests may reveal early Parkinson's clues
- Colon tissue may hold clues to telling Parkinson's apart from Look-Alike diseases
- A genetic roadmap for Parkinson's: testing thousands to unlock clues
- Can gentle touch therapy calm Parkinson's tremors?
- Stem cell infusions aim to slow Parkinson's progression
- Can an inhaled levodopa ease Parkinson's OFF episodes? a study asks patients.